Suchergebnisse - "Pouwels, Xavier G L V"

PubPharm (28)

1

Introducing Open Science in Teaching Health Economic Modelling

enthalten in: PharmacoEconomics - open | 2024

von Pouwels, X. | Koffijberg, H.

2

Validating health economic models with the Probabilistic Analysis Check dashBOARD (PACBOARD)

enthalten in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2024

von Pouwels, X. | Kroeze, K. | van der Linden, N. | +2

3

Cost-effectiveness of home-based screening of the general population for albuminuria to prevent progression of cardiovascular and kidney disease

enthalten in: EClinicalMedicine | 2024

von Pouwels, X. | van Mil, D. | Kieneker, L. | +9

4

Introducing Open Science in Teaching Health Economic Modelling

enthalten in: PharmacoEconomics - open | 2024

von Pouwels, X. | Koffijberg, H.

5

Cost-effectiveness of screening for chronic kidney disease : existing evidence and knowledge gaps

enthalten in: Clinical kidney journal | 2024

von van Mil, D. | Pouwels, X. | Heerspink, H. | +1

6

Response to "UNCERTAINTY MANAGEMENT IN REGULATORY AND HEALTH TECHNOLOGY ASSESSMENT DECISION-MAKING ON DRUGS : GUIDANCE OF THE HTAi-DIA WORKING GROUP"

enthalten in: International journal of technology assessment in health care | 2023

von Grimm, S. | Pouwels, X. | Ramaekers, B. | +3

7

Opportunities and Barriers to the Development and Use of Open Source Health Economic Models : A Survey

enthalten in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2022

von Pouwels, X. | Sampson, C. | Arnold, R. | +18

ErratumIn: Value Health. 2023 Jul;26(7):1135. - PMID 36549955

8

Efficacy, cost-minimization, and budget impact of a personalized discharge letter for basal cell carcinoma patients to reduce low-value follow-up care

enthalten in: PloS one | 2022

von van Egmond, S. | van Vliet, E. | Wakkee, M. | +14

9

Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma : An Evidence Review Group Perspective of a NICE Single Technology Appraisal

enthalten in: PharmacoEconomics | 2021

von Witlox, W. | Grimm, S. | Riemsma, R. | +11

10

Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands : A State Transition Model

enthalten in: Medical decision making : an international journal of the Society for Medical Decision Making | 2020

von Kremer, I. | Hiligsmann, M. | Carlson, J. | +6